# Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

> **NCT02618408** · PHASE3 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 333 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** SPN-810 (18 mg)
- **DRUG:** SPN-810 (36 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02618408
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-25
- **Primary completion:** 2019-09-04
- **Final completion:** 2019-10-24
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02618408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02618408, "Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02618408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*